BioSpace News Archive

GoHealth, Inc. (“GoHealth”) (Nasdaq: GOCO), a leading health insurance marketplace, today announced the pricing of its initial public offering of 43,500,000 shares of its Class A common stock at a public offering price of $21.00 per share

MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results for the three-months ended March 31, 2020, which are also available on SEDAR (www.sedar.com).

The poultry health market is set to see growth at an impressive CAGR of 7.6% between 2017 and 2025, owing to increasing levels of awareness regarding poultry diseases, owing to a recent study by Transparency Market Research.

Surgical care is one of the most essential courses of actions required to effectively manage a variety of health conditions including obstructed labor, injuries, malignancy, cardiovascular disease and infections.

Personalized medications have gained traction in recent years. This popularity is the key factor that is driving the growth of global compounding pharmacies.

Cold plasma, additionally called non-warm plasma or non-balance plasma, is a sort of plasma—ordinarily known as the fourth condition of issue—which has gas particles show at direct temperature and electrons at moderately high temperatures.

In vitro testing demonstrates that tafenoquine exhibits antiviral activity against SARS-CoV-2

In their latest paper published in the online prepublication by the peer-reviewed journal Current Protocols, scientists and cGMP operation managers at Allele Biotechnology present a series of step-by-step protocols for manufacturers of iPSC and other types of stem cells with streamlined cleanroom practices for growing clinical grade cell products.

EyeGate Pharmaceuticals, Inc., a clinical-stage company focused on developing products for treating disorders of the eye, announced that based on feedback from a meeting with the U.S.

Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune disease, announced that the first patient has been dosed in a Phase 1 study of NX-13, the Company’s novel, orally administered therapeutic candidate for the treatment of inflammatory bowel disease.